Eyeing variants, Adagio starts phase 1 trial of COVID-19 antibody

Adagio Therapeutics has dosed the first subject with its anti-SARS-CoV-2 antibody. Administration of the candidate, which Adagio expects to be effective against coronavirus variants, continues the rapid rise of the biotech helmed by Tillman Gerngross, Ph.D.